NFXBio: Deal or Die – A Guide to TechBio Business Development and Strategy

There are two parts to building a bioplatform: you have to focus on the science, then you have to think about the business side. When do you partner? When do you develop your own products? How can you determine the real value of a deal? How do you build a strategic network? What avenues are Founders overlooking right now? These are questions our companies ask us all the time. Today, Head of NFXBio Omri Amirav-Dory, Yael Gruenbaum-Cohen, a venture partner at aMoon Fund, and Peter Nell, former Chief Business Officer and head of Therapeutics at Mammoth Biosciences, are charting a roadmap for successful bioplatform business development.